An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Long-acting β adrenoceptor agonists (LABAs, more specifically, long-acting β2 adrenergic receptor agonists) are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol, long-acting β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salb

Property Value
dbo:abstract
  • ناهض المستقبلة الأدرينية-بيتا مديد المفعول (بالإنجليزية: Long-acting beta-adrenoceptor agonist)‏ ويُعرف اختصارًا LABA، هو دواء يُوصف عادةً لمرضى الربو المستمر المُتوسط أو الشديد، أو لمرضى داء الانسداد الرئوي المزمن (COPD). في 18 فبراير 2011، أعلنت إدارة الغذاء والدواء أنَّ هذه الناهضات سليمة. (ar)
  • En farmacología, los agonistas adrenérgicos de acción larga, conocidos como LABA por las iniciales de su denominación en inglés long-acting beta-adrenoceptor agonist, son medicamentos que se emplean en el tratamiento de enfermedades pulmonares, principalmente asma bronquial y enfermedad pulmonar obstructiva crónica, por su capacidad de producir broncodilatación, pertenecen al grupo terapéutico de los agonistas beta-adrenérgicos, su duración de acción es larga, entre 12 y 14 horas, a diferencia de los agonistas beta-adrenérgicos de acción corta (SABA).​ (es)
  • Long-acting β adrenoceptor agonists (LABAs, more specifically, long-acting β2 adrenergic receptor agonists) are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol, long-acting β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salbutamol. Their long duration of action is due to the addition of a long, lipophilic side-chain that binds to an exosite on adrenergic receptors. This allows the active portion of the molecule to continuously bind and unbind at β2 receptors in the smooth muscle in the lungs. (en)
dbo:thumbnail
dbo:wikiPageID
  • 3006665 (xsd:integer)
dbo:wikiPageLength
  • 16026 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1110171709 (xsd:integer)
dbo:wikiPageWikiLink
dbp:caption
  • Salmeterol—an example of long-acting β2 adrenoreceptor agonist (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdfs:comment
  • ناهض المستقبلة الأدرينية-بيتا مديد المفعول (بالإنجليزية: Long-acting beta-adrenoceptor agonist)‏ ويُعرف اختصارًا LABA، هو دواء يُوصف عادةً لمرضى الربو المستمر المُتوسط أو الشديد، أو لمرضى داء الانسداد الرئوي المزمن (COPD). في 18 فبراير 2011، أعلنت إدارة الغذاء والدواء أنَّ هذه الناهضات سليمة. (ar)
  • En farmacología, los agonistas adrenérgicos de acción larga, conocidos como LABA por las iniciales de su denominación en inglés long-acting beta-adrenoceptor agonist, son medicamentos que se emplean en el tratamiento de enfermedades pulmonares, principalmente asma bronquial y enfermedad pulmonar obstructiva crónica, por su capacidad de producir broncodilatación, pertenecen al grupo terapéutico de los agonistas beta-adrenérgicos, su duración de acción es larga, entre 12 y 14 horas, a diferencia de los agonistas beta-adrenérgicos de acción corta (SABA).​ (es)
  • Long-acting β adrenoceptor agonists (LABAs, more specifically, long-acting β2 adrenergic receptor agonists) are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol, long-acting β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salb (en)
rdfs:label
  • ناهض المستقبلة الأدرينية-بيتا مديد المفعول (ar)
  • Agonista adrenérgico de acción larga (es)
  • Long-acting beta-adrenoceptor agonist (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageDisambiguates of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:class of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License